TISIDB

Summary
Symbol	NANS
Name	N-acetylneuraminic acid synthase
Aliases	sialic acid synthase; HEL-S-100; N-acetylneuraminate synthase; N-acetylneuraminate-9-phosphate synthase; N-a ......
Chromosomal Location	9p24.1-p23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	-
Domain	PF03102 NeuB family
Function	Produces N-acetylneuraminic acid (Neu5Ac) and 2-keto-3-deoxy-D-glycero-D-galacto-nononic acid (KDN). Can also use N-acetylmannosamine 6-phosphate and mannose 6-phosphate as substrates to generate phosphorylated forms of Neu5Ac and KDN, respectively.

> Gene Ontology [ TOP ]
Biological Process	GO:0000271 polysaccharide biosynthetic process GO:0005976 polysaccharide metabolic process GO:0008653 lipopolysaccharide metabolic process GO:0009103 lipopolysaccharide biosynthetic process GO:0016051 carbohydrate biosynthetic process GO:0033692 cellular polysaccharide biosynthetic process GO:0034637 cellular carbohydrate biosynthetic process GO:0044262 cellular carbohydrate metabolic process GO:0044264 cellular polysaccharide metabolic process GO:0044723 single-organism carbohydrate metabolic process GO:1903509 liposaccharide metabolic process
Molecular Function	GO:0008781 N-acylneuraminate cytidylyltransferase activity GO:0016765 transferase activity, transferring alkyl or aryl (other than methyl) groups GO:0016779 nucleotidyltransferase activity GO:0047444 N-acylneuraminate-9-phosphate synthase activity GO:0050462 N-acetylneuraminate synthase activity GO:0070567 cytidylyltransferase activity
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa00520 Amino sugar and nucleotide sugar metabolism hsa01100 Metabolic pathways
Reactome	R-HSA-446203: Asparagine N-linked glycosylation R-HSA-446193: Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein R-HSA-392499: Metabolism of proteins R-HSA-597592: Post-translational protein modification R-HSA-4085001: Sialic acid metabolism R-HSA-446219: Synthesis of substrates in N-glycan biosythesis

Summary
Symbol	NANS
Name	N-acetylneuraminic acid synthase
Aliases	sialic acid synthase; HEL-S-100; N-acetylneuraminate synthase; N-acetylneuraminate-9-phosphate synthase; N-a ......
Chromosomal Location	9p24.1-p23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between NANS and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	NANS
Name	N-acetylneuraminic acid synthase
Aliases	sialic acid synthase; HEL-S-100; N-acetylneuraminate synthase; N-acetylneuraminate-9-phosphate synthase; N-a ......
Chromosomal Location	9p24.1-p23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of NANS in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	logFC: -2.20; FDR: 0.04630	Resistant to T cell-mediated killing
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	NANS
Name	N-acetylneuraminic acid synthase
Aliases	sialic acid synthase; HEL-S-100; N-acetylneuraminate synthase; N-acetylneuraminate-9-phosphate synthase; N-a ......
Chromosomal Location	9p24.1-p23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of NANS in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.203	0.506
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.051	0.985
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.393	0.849
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.301	0.357
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.379	0.84
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.197	0.93
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.013	0.971
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.091	0.954
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.066	0.97
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.152	0.927
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.063	0.98
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.109	0.223

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of NANS in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	3.7	0.27
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	3.7	0.314
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	NANS
Name	N-acetylneuraminic acid synthase
Aliases	sialic acid synthase; HEL-S-100; N-acetylneuraminate synthase; N-acetylneuraminate-9-phosphate synthase; N-a ......
Chromosomal Location	9p24.1-p23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NANS. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	NANS
Name	N-acetylneuraminic acid synthase
Aliases	sialic acid synthase; HEL-S-100; N-acetylneuraminate synthase; N-acetylneuraminate-9-phosphate synthase; N-a ......
Chromosomal Location	9p24.1-p23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NANS. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NANS. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	NANS
Name	N-acetylneuraminic acid synthase
Aliases	sialic acid synthase; HEL-S-100; N-acetylneuraminate synthase; N-acetylneuraminate-9-phosphate synthase; N-a ......
Chromosomal Location	9p24.1-p23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NANS. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	NANS
Name	N-acetylneuraminic acid synthase
Aliases	sialic acid synthase; HEL-S-100; N-acetylneuraminate synthase; N-acetylneuraminate-9-phosphate synthase; N-a ......
Chromosomal Location	9p24.1-p23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of NANS expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	NANS
Name	N-acetylneuraminic acid synthase
Aliases	sialic acid synthase; HEL-S-100; N-acetylneuraminate synthase; N-acetylneuraminate-9-phosphate synthase; N-a ......
Chromosomal Location	9p24.1-p23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between NANS and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	NANS
Name	N-acetylneuraminic acid synthase
Aliases	sialic acid synthase; HEL-S-100; N-acetylneuraminate synthase; N-acetylneuraminate-9-phosphate synthase; N-a ......
Chromosomal Location	9p24.1-p23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting NANS collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse NANS